Looks like UNS has a future, page-11

rodfest , feels different this time
- the products are now already largely developed
- focus now on their most competitive and profitable lines for the customer funding opportunities - like Amgen's (ie. they pay some upfronts and / or lend for what they want, then get to buy their product at some discount, which can serve to pay back part / or all the loan over time etc.)
- gone is the grandiose language of years past, which gave shorts a feeding frenzy